Abstract Details

Title Socioeconomic and Racial Disparities in Guillain-Barré Syndrome Outcomes

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 11-018

Objective Assess the impact of socioeconomic and racial factors on outcomes in Guillain- Barré Syndrome (GBS).

Background GBS is an acute inflammatory demyelinating polyradiculoneuropathy with potentially severe outcomes. However, the impact of socioeconomic and racial factors has not been previously investigated.

Design/Methods We analyzed inpatients from the National Inpatient Sample from 2016-2021. Multivariable logistic regression models were constructed to assess the association between socioeconomic and demographic factors and three outcomes: in-hospital mortality, non-routine discharge, and prolonged hospitalization (length of stay >14 days). All models adjusted for a broad range of covariates including age, sex, and Elixhauser comorbidities.

Results

A total of 55,900 hospitalizations with a primary diagnosis of GBS were included. After adjusting for covariates, multivariable logistic regression models revealed several key associations between socioeconomic and racial factors and GBS outcomes:

Individuals from the wealthiest ZIP codes had lower odds of in-hospital mortality (OR 0.57 95% CI [0.35 – 0.95] p = 0.029).
Medicare and Medicaid beneficiaries had higher odds of non-routine discharges (OR 1.50 95% CI [1.31 – 1.72] p < 0.001, and OR 1.21 95% CI [1.07 – 1.38] p = 0.004, respectively).
Black patients had higher odds of non-routine discharge (OR 1.28 95% CI [1.08 – 1.52] p = 0.004).
Hispanic patients had increased odds of prolonged hospitalization OR (1.19 95% CI [1.02 – 1.38] p = 0.028).
Medicaid beneficiaries and self-pay patients had increased odds of prolonged hospitalization (OR 1.46 95% CI [1.27 – 1.69] p <0.001, and OR 1.32 95% CI [1.05 – 1.66] p = 0.016, respectively).

Conclusions

This study highlights important socioeconomic and racial disparities in GBS. These findings underscore the need for targeted interventions and policy changes to address healthcare disparities in GBS management.

Authors/Disclosures
Yagiz M. Altun, MD, PhD (Albert Einstein College of Medicine) PRESENTER	Dr. Altun has nothing to disclose.
Edward Bader, MD	Dr. Bader has received intellectual property interests from a discovery or technology relating to health care.
Siyu Yan, MS	Ms. Yan has nothing to disclose.
Lauren Gluck, MD (Montefiore Medical Center)	Dr. Gluck has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeautics. Dr. Gluck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Gluck has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen Rare Disease. Dr. Gluck has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Gluck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb.

��ɫ��

��ɫ��